FDA Cracks Eggs Over Safety Regs: Comment by April!
Published Date: 3/13/2026
Notice
Summary
The FDA is updating how it collects info about egg safety rules to keep food safe and healthy. This affects state and local food safety teams who help protect us from foodborne illnesses. They’re asking for your thoughts by April 13, 2026, to make sure the process is smooth and effective—no big cost changes expected!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
State and Tribal Reporting Burden Estimates
FDA estimates reporting burden per submission at 569 hours. For ERPS submissions FDA estimates 2 respondents, 1 response each, totaling 1,138 reporting hours; for AFRPS submissions FDA estimates 25 respondents, 1 response each, totaling 14,225 reporting hours; combined reporting burden is 15,363 hours. FDA also estimates annual recordkeeping burden totaling 11,800 hours (ERPS recordkeeping 800 hours; AFRPS recordkeeping 11,000 hours) and states there are no capital or operating and maintenance costs associated with this collection.
Revised Egg Safety Program Standards
The FDA revised the Egg Regulatory Program Standards (ERPS) to reflect lessons learned from the 2021 ERPS and updated program definitions, all 10 program standards, appendices, and assessment worksheets. States that have adopted ERPS will use the revised worksheets and forms, perform a baseline self-assessment in the first year of enrollment, and submit comprehensive reviews in subsequent years to verify conformance and improve program effectiveness and clarity.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-04939 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Mammography Standards Quality Act Requirements
The FDA is asking for public feedback on renewing rules that keep mammogram centers safe and reliable. These rules affect mammography facilities, making sure their equipment, staff, and practices meet high standards. Comments are due by April 13, 2026, and this process helps protect patients without adding extra costs.
Next: 2026-04941 — 2026 Environmental Financial Advisory Board (EFAB) Federal Advisory Committee Act (FACA) Charter 2-Year Renewal
The EPA is renewing the Environmental Financial Advisory Board (EFAB) for two more years to keep getting smart ideas on how to fund environmental and public health projects without spending extra taxpayer money. This board helps the EPA find ways to save money and attract private investments. The renewal keeps the board active through 2028 with a budget of about $287,000 per year.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in